A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer (FRACTION-GC)

A Phase 2, Fast Real-Time Assessment of Combination Therapies in Immuno-Oncology Study in Participants with Advanced Gastric Cancer (FRACTION-Gastric)

Investigator
Trial Phase
Phase II
Study Number
NCT02935634
Local Study ID
20162429
Trial Contact Phone
800-804-8824 / 206-606-1024
Summary
The purpose of this study is to determine whether Nivolumab in combination with other therapies is more effective than Nivolumab in combination with Ipilimumab in treating patients/subjects with advanced gastric cancer.
Trial Eligibility

*For Eligibility information, look up the trial at NIH by clicking on the Study Number above.*
Other eligibility criteria may apply.

Trial Exclusions

Other exclusion criteria may apply.

Trial Keywords
Esophageal Cancer; Gastric Cancer; Gastrointestinal Cancer; Solid Tumors; Stomach Cancer; Immunotherapy; Esophageal Diseases; Digestive System Diseases
See this trial at ClinicalTrials.gov

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.